Eli Lilly partner Chi-Med sees shares tank as its newly approved cancer drug flunks PhIII lung cancer trial
Shares of Hutchison China MediTech — better known as Chi-Med — took a nasty hit Friday morning with the news that their lead drug fruquintinib failed a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
